These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 23686001)

  • 1. Contrast sensitivity evaluation in high risk proliferative diabetic retinopathy treated with panretinal photocoagulation associated or not with intravitreal bevacizumab injections: a randomised clinical trial.
    Preti RC; Ramirez LM; Monteiro ML; Carra MK; Pelayes DE; Takahashi WY
    Br J Ophthalmol; 2013 Jul; 97(7):885-9. PubMed ID: 23686001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravitreal bevacizumab and/or macular photocoagulation as a primary treatment for diffuse diabetic macular edema.
    Solaiman KA; Diab MM; Abo-Elenin M
    Retina; 2010; 30(10):1638-45. PubMed ID: 20838357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high-risk proliferative diabetic retinopathy.
    Filho JA; Messias A; Almeida FP; Ribeiro JA; Costa RA; Scott IU; Jorge R
    Acta Ophthalmol; 2011 Nov; 89(7):e567-72. PubMed ID: 21726427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural and functional assessment of macula in patients with high-risk proliferative diabetic retinopathy submitted to panretinal photocoagulation and associated intravitreal bevacizumab injections: a comparative, randomised, controlled trial.
    Preti RC; Vasquez Ramirez LM; Ribeiro Monteiro ML; Pelayes DE; Takahashi WY
    Ophthalmologica; 2013; 230(1):1-8. PubMed ID: 23689115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repeated intravitreal bevacizumab injection with and without macular grid photocoagulation for treatment of diffuse diabetic macular edema.
    Solaiman KA; Diab MM; Dabour SA
    Retina; 2013 Sep; 33(8):1623-9. PubMed ID: 23538584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CHOROIDAL THICKNESS CHANGES IN PROLIFERATIVE DIABETIC RETINOPATHY TREATED WITH PANRETINAL PHOTOCOAGULATION VERSUS PANRETINAL PHOTOCOAGULATION WITH INTRAVITREAL BEVACIZUMAB.
    Roohipoor R; Sharifian E; Ghassemi F; Riazi-Esfahani M; Karkhaneh R; Fard MA; Zarei M; Modjtahedi BS; Moghimi S
    Retina; 2016 Oct; 36(10):1997-2005. PubMed ID: 27046456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study).
    Tonello M; Costa RA; Almeida FP; Barbosa JC; Scott IU; Jorge R
    Acta Ophthalmol; 2008 Jun; 86(4):385-9. PubMed ID: 17995982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema.
    Soheilian M; Ramezani A; Obudi A; Bijanzadeh B; Salehipour M; Yaseri M; Ahmadieh H; Dehghan MH; Azarmina M; Moradian S; Peyman GA
    Ophthalmology; 2009 Jun; 116(6):1142-50. PubMed ID: 19376585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravitreal bevacizumab plus grid laser photocoagulation or intravitreal bevacizumab or grid laser photocoagulation for diffuse diabetic macular edema: results of the Pan-american Collaborative Retina Study Group at 24 months.
    Arevalo JF; Lasave AF; Wu L; Diaz-Llopis M; Gallego-Pinazo R; Alezzandrini AA; Berrocal MH;
    Retina; 2013 Feb; 33(2):403-13. PubMed ID: 23222389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema.
    Soheilian M; Ramezani A; Bijanzadeh B; Yaseri M; Ahmadieh H; Dehghan MH; Azarmina M; Moradian S; Tabatabaei H; Peyman GA
    Retina; 2007; 27(9):1187-95. PubMed ID: 18046223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two-year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema.
    Soheilian M; Garfami KH; Ramezani A; Yaseri M; Peyman GA
    Retina; 2012 Feb; 32(2):314-21. PubMed ID: 22234244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravitreal triamcinolone and bevacizumab as adjunctive treatments to panretinal photocoagulation in diabetic retinopathy.
    Cho WB; Moon JW; Kim HC
    Br J Ophthalmol; 2010 Jul; 94(7):858-63. PubMed ID: 20606024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2.
    Michaelides M; Kaines A; Hamilton RD; Fraser-Bell S; Rajendram R; Quhill F; Boos CJ; Xing W; Egan C; Peto T; Bunce C; Leslie RD; Hykin PG
    Ophthalmology; 2010 Jun; 117(6):1078-1086.e2. PubMed ID: 20416952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Panretinal photocoagulation combined with intravitreal bevacizumab in high-risk proliferative diabetic retinopathy.
    Cho WB; Oh SB; Moon JW; Kim HC
    Retina; 2009 Apr; 29(4):516-22. PubMed ID: 19262436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized controlled trial of panretinal photocoagulation with and without intravitreal ranibizumab in treatment-naive eyes with non-high-risk proliferative diabetic retinopathy.
    Ferraz DA; Vasquez LM; Preti RC; Motta A; Sophie R; Bittencourt MG; Sepah YJ; Monteiro ML; Nguyen QD; Takahashi WY
    Retina; 2015 Feb; 35(2):280-7. PubMed ID: 25272318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravitreal triamcinolone as an adjunct to standard laser therapy in coexisting high-risk proliferative diabetic retinopathy and clinically significant macular edema.
    Mirshahi A; Shenazandi H; Lashay A; Faghihi H; Alimahmoudi A; Dianat S
    Retina; 2010 Feb; 30(2):254-9. PubMed ID: 20057344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ranibizumab Plus Panretinal Photocoagulation versus Panretinal Photocoagulation Alone for High-Risk Proliferative Diabetic Retinopathy (PROTEUS Study).
    Figueira J; Fletcher E; Massin P; Silva R; Bandello F; Midena E; Varano M; Sivaprasad S; Eleftheriadis H; Menon G; Amaro M; Ayello Scheer S; Creuzot-Garcher C; Nascimento J; Alves D; Nunes S; Lobo C; Cunha-Vaz J;
    Ophthalmology; 2018 May; 125(5):691-700. PubMed ID: 29395119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repeated intravitreal bevacizumab (Avastin(®)) treatment of persistent new vessels in proliferative diabetic retinopathy after complete panretinal photocoagulation.
    Schmidinger G; Maar N; Bolz M; Scholda C; Schmidt-Erfurth U
    Acta Ophthalmol; 2011 Feb; 89(1):76-81. PubMed ID: 21272288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors Associated with Worsening Proliferative Diabetic Retinopathy in Eyes Treated with Panretinal Photocoagulation or Ranibizumab.
    Bressler SB; Beaulieu WT; Glassman AR; Gross JG; Jampol LM; Melia M; Peters MA; Rauser ME;
    Ophthalmology; 2017 Apr; 124(4):431-439. PubMed ID: 28161147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
    Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
    Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.